Important Community Notice from the Hemophilia Foundation of Maryland

Takeda Announces Global Discontinuation of HEMOFIL® M and RECOMBINATE® Takeda has announced its decision to globally discontinue HEMOFIL® M [Antihemophilic Factor (Human), Method M, Monoclonal Purified] and RECOMBINATE® [Antihemophilic Factor (Recombinant)]. Takeda recognizes the significant impact this decision may have on patients who rely on these medications and is committed to supporting the community throughout this transition.

Product Availability and Transition Plans

• • Takeda will continue to supply HEMOFIL M and RECOMBINATE until inventory is depleted or expires, which is expected to occur by mid-2026.

• • It is important to note that there are no quality or safety concerns with these products.

When the time comes for patients to transition to an alternative treatment, Takeda offers options within its factor VIII portfolio that may meet individual needs:

• • ADVATE® [Antihemophilic Factor (Recombinant)]

• • ADYNOVATE® [Antihemophilic Factor (Recombinant), PEGylated]

Next Steps

For more information on Takeda’s alternative treatment options, please refer to the attached Patient Brochure and Patient Letter.  We encourage patients to begin discussions with their healthcare providers as early as possible to allow sufficient time for long-term treatment planning. Additional resources are available at www.HemophiliaJourney.com.

Contact Information

For further inquiries or to discuss your options, please reach out to our Maryland Takeda representative: Jan Martin, MSN, RN-BC, CPN Community Education Specialist Takeda Pharmaceuticals U.S.A., Inc. Mobile: +1 440-514-8117 Email: janet.martin@takeda.com